IK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic TEAD signaling IK-930’s differentiated paralog…
BRISBANE, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics…
– Preclinical data supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission…
New tissue imaging tool designed to revolutionize clinical researchSOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Standard BioTools…
BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 GP-2250’s antineoplastic effects on ovarian cancer cells…
Roger Estafanos ITM announces a new General Manager for U.S. ITM U.S. Headquarters ITM Opens U.S. Headquarters in PrincetonGarching /…
Providence, RI, April 17, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (“Ocean”), a biopharma company working to accelerate the development…
VIP236, a SMDC with a novel optimized camptothecin (CPT) payload, demonstrated significant activity in patient-derived (PDX) mouse models and metastatic…
LONDON, April 17, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T…